Gould3: sample sizes

Number of animals tested for each measure in this project, by strain and sex.       Cells with N < 5 are colored pink.


More info about these strains
Gould3 measure Sex 129S6/SvEvTac A/J BALB/cByJ C3H/HeJ C57BL/6J CBA/J DBA/1J DBA/2J
grooming_0   withdrawal study group, number of grooming episodes, 20 min test , control   47301 Female
Male 12 14 12 14 14 14 14 12
grooming_3   withdrawal study group, number of grooming episodes, 20 min test , dose: 3 mg   47302 Female
Male 10 10 10 10 10 10 10 10
grooming_6   withdrawal study group, number of grooming episodes, 20 min test , dose: 6.3 mg   47303 Female
Male 10 10 10 10 10 10 10 10
grooming_12   withdrawal study group, number of grooming episodes, 20 min test , dose: 12 mg   47304 Female
Male 10 10 10 9 10 10 10 10
scratching_0   withdrawal study group, number of scratching episodes, 20 min test , control   47306 Female
Male 12 14 12 14 14 14 14 12
scratching_3   withdrawal study group, number of scratching episodes, 20 min test , dose: 3 mg   47307 Female
Male 10 10 10 10 10 10 10 10
scratching_6   withdrawal study group, number of scratching episodes, 20 min test , dose: 6.3 mg   47308 Female
Male 10 10 10 10 10 10 10 10
scratching_12   withdrawal study group, number of scratching episodes, 20 min test , dose: 12 mg   47309 Female
Male 10 10 10 9 10 10 10 10
jumping_0   withdrawal study group, number of jumping episodes, 20 min test , control   47311 Female
Male 12 14 12 14 14 14 14 12
jumping_3   withdrawal study group, number of jumping episodes, 20 min test , dose: 3 mg   47312 Female
Male 10 10 10 10 10 10 10 10
jumping_6   withdrawal study group, number of jumping episodes, 20 min test , dose: 6.3 mg   47313 Female
Male 10 10 10 10 10 10 10 10
jumping_12   withdrawal study group, number of jumping episodes, 20 min test , dose: 12 mg   47314 Female
Male 10 10 10 9 10 10 10 10
EPM_pct_closed_0   withdrawal study group, percentage of time in closed arms , control   47321 Female
Male 12 14 12 13 14 13 12 12
EPM_pct_closed_3   withdrawal study group, percentage of time in closed arms , dose: 3 mg   47322 Female
Male 10 10 10 9 10 8 10 10
EPM_pct_closed_6   withdrawal study group, percentage of time in closed arms , dose: 6.3 mg   47323 Female
Male 9 10 10 9 10 9 10 10
EPM_pct_closed_12   withdrawal study group, percentage of time in closed arms , dose: 12 mg   47324 Female
Male 10 10 10 9 10 9 10 10
EPM_pct_open_0   withdrawal study group, percentage of time in open arms , control   47326 Female
Male 12 14 12 13 14 13 12 12
EPM_pct_open_3   withdrawal study group, percentage of time in open arms , dose: 3 mg   47327 Female
Male 10 10 10 9 10 8 10 10
EPM_pct_open_6   withdrawal study group, percentage of time in open arms , dose: 6.3 mg   47328 Female
Male 9 10 10 9 10 9 10 10
EPM_pct_open_12   withdrawal study group, percentage of time in open arms , dose: 12 mg   47329 Female
Male 10 10 10 9 10 9 10 10
EPM_pct_center_0   withdrawal study group, percentage of time in center , control   47331 Female
Male 12 14 12 13 14 13 12 12
EPM_pct_center_3   withdrawal study group, percentage of time in center , dose: 3 mg   47332 Female
Male 10 10 10 9 10 8 10 10
EPM_pct_center_6   withdrawal study group, percentage of time in center , dose: 6.3 mg   47333 Female
Male 9 10 10 9 10 9 10 10
EPM_pct_center_12   withdrawal study group, percentage of time in center , dose: 12 mg   47334 Female
Male 10 10 10 9 10 9 10 10
FC_immediate_0   withdrawal study group, percent immobility in training chamber after first stimulus pairing , control   47341 Female
Male 12 16 14 14 14 14 14 14
FC_immediate_3   withdrawal study group, percent immobility in training chamber after first stimulus pairing , dose: 3 mg   47342 Female
Male 10 10 10 10 10 10 10 14
FC_immediate_6   withdrawal study group, percent immobility in training chamber after first stimulus pairing , dose: 6.3 mg   47343 Female
Male 9 12 10 10 10 10 10 14
FC_immediate_12   withdrawal study group, percent immobility in training chamber after first stimulus pairing , dose: 12 mg   47344 Female
Male 10 14 10 9 10 10 10 14
FC_context_0   withdrawal study group, percent immobility in training chamber, 24h after fear conditioning , control   47346 Female
Male 12 16 14 14 14 14 14 14
FC_context_3   withdrawal study group, percent immobility in training chamber, 24h after fear conditioning , dose 3 mg   47347 Female
Male 10 10 10 10 10 10 10 14
FC_context_6   withdrawal study group, percent immobility in training chamber, 24h after fear conditioning , dose 6.3 mg   47348 Female
Male 9 12 10 10 10 10 10 14
FC_context_12   withdrawal study group, percent immobility in training chamber, 24h after fear conditioning , dose 12 mg   47349 Female
Male 10 14 10 9 10 10 10 14
FC_preCS_0   withdrawal study group, percent immobility in altered context chamber, pre-cue , control   47361 Female
Male 12 16 14 14 14 14 14 14
FC_preCS_3   withdrawal study group, percent immobility in altered context chamber, pre-cue , dose: 3 mg   47362 Female
Male 10 10 10 10 10 10 10 14
FC_preCS_6   withdrawal study group, percent immobility in altered context chamber, pre-cue , dose: 6.3 mg   47363 Female
Male 9 12 10 10 10 10 10 14
FC_preCS_12   withdrawal study group, percent immobility in altered context chamber, pre-cue , dose: 12 mg   47364 Female
Male 10 14 10 9 10 10 10 14
FC_CS_0   withdrawal study group, percent immobility in altered context chamber, cue , control   47366 Female
Male 12 16 14 14 14 14 14 14
FC_CS_3   withdrawal study group, percent immobility in altered context chamber, cue , dose: 3 mg   47367 Female
Male 10 10 10 10 10 10 10 14
FC_CS_6   withdrawal study group, percent immobility in altered context chamber, cue , dose: 6.3 mg   47368 Female
Male 9 12 10 10 10 10 10 14
FC_CS_12   withdrawal study group, percent immobility in altered context chamber, cue , dose: 12 mg   47369 Female
Male 10 14 10 9 10 10 10 14